Announcements Trials
Browse Landscape

Phase

Phase 1 19Phase 2 13Phase NA 4Phase 3 3Phase 1/2 3Phase EARLY_PHASE1 2

Status

Completed 23Terminated 7Active not recruiting 5Recruiting 3Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Classical hematology 1

Conditions

Breast Neoplasms 129Carcinoma, Non-Small-Cell Lung 101Prostatic Neoplasms 62Colorectal Neoplasms 49Nasopharyngeal Carcinoma 45Neoplasms 44Multiple Myeloma 42Stomach Neoplasms 35Neoplasm Metastasis 32Leukemia, Myeloid, Acute 32Ovarian Neoplasms 31Lung Neoplasms 31Carcinoma, Hepatocellular 29Squamous Cell Carcinoma of Head and Neck 27Rectal Neoplasms 27Pancreatic Neoplasms 26Triple Negative Breast Neoplasms 25Recurrence 25Small Cell Lung Carcinoma 21Brain Neoplasms 21Esophageal Neoplasms 20Colonic Neoplasms 20Uterine Cervical Neoplasms 19Lymphoma, Large B-Cell, Diffuse 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Leukemia, Lymphocytic, Chronic, B-Cell 16Esophageal Squamous Cell Carcinoma 16Carcinoma, Renal Cell 16Myasthenia Gravis 15

Interventions

bomedemstat 1N(4)-oleylcytosine arabinoside 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Primary Myelofibrosis × Clear all
NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05198960 2026-03-20

AVAJAK

University Hospital, Brest

Phase 3 Recruiting
1,308 enrolled
Classical hematologyMyeloid

Hemorrhage, Polycythemia Vera, Thrombocythemia, Essential, Venous Thromboembolism, Primary Myelofibrosis

NCT06468033 2025-08-13

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

PharmaEssentia

Phase 3 Recruiting
150 enrolled
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡